Amgen Inc.

The provided transcript from Amgen's Q4 2020 earnings call does not explicitly mention any current or planned new fundraising through debt or equity. Key points related to capital and financial strategy include: - Amgen acknowledges ongoing intense competition for capital in the biopharma sector. - The company emphasizes the importance of execution in innovation and growth. - They highlight continuing investments in R&D and maintaining flexibility for internal and external investments. - Peter Griffith, CFO, mentions exercising financial discipline and maintaining a flexible approach to capital allocation. - Biosimilars remain a strong capital allocation area for Amgen. - No specific announcements or plans regarding new debt issuance or equity fundraising were disclosed during this call. Thus, no explicit new fundraising via debt or equity was communicated at this time.

- Amgen plans to increase R&D investment in 2021, focusing on advancing promising mid-stage pipeline candidates. - Significant capital is allocated to biosimilars, which remain a strong area of expertise and execution. - Investments are being made to expand and optimize the commercial model, including digital capabilities and commercial field restructuring. - Strategic investments in technology platforms such as induced proximity (protein degradation and multi-specific targeted drugs) to expand druggable targets. - Capital allocation supports internal innovation and external opportunity pursuit, including acquisitions like New Evolution to build capabilities. - Ongoing investments in expanding global presence, especially in markets like China, Japan, and other emerging regions. - Continued commitment to ESG initiatives potentially influencing capital deployment (e.g., carbon neutrality and waste reduction by 2027).

- Amgen expects continued volume growth from key products including Prolia, Otezla, Repatha, EVENITY, Aimovig, and innovative oncology portfolio in 2021. - Anticipated continued momentum for Repatha globally, driven by international growth and stable US net prices. - Otezla growth expected through US increased penetration plus international market expansions (e.g., Japan, Australia). - Biosimilar sales projected to grow, partially offset by net selling price declines due to competition. - Parsabiv sales anticipated to decline 40-50% in 2021 due to reimbursement changes and generic competition. - Operating margin estimated at roughly 50% in 2021 with revenue guidance of $25.8 billion to $26.6 billion. - Anticipated mid-single digit net selling price declines industry-wide affecting revenue. - Aimovig volumes showed 21% YoY growth in Q4 despite some COVID-related patient start impacts. - Overall, Amgen confident in sustained growth fueled by innovative launches like sotorasib and tezepelumab, digital commercial model, and international expansion.

- Amgen expects continued revenue growth driven by volume growth in key products such as Prolia, Otezla, Repatha, EVENITY, and oncology portfolio amidst ongoing price declines (~mid-single digit). - 2021 revenue guidance: $25.8 billion to $26.6 billion. - 2021 non-GAAP EPS guidance: $12.12 to $13.17 per share, reflecting 5% non-GAAP EPS growth year-over-year. - Operating expenses projected to grow around 7% in 2021 due to increased investment in R&D and commercial launches. - Operating margin expected to be roughly 50% in 2021. - Non-GAAP tax rate guidance of 13-14%. - Capital expenditures approximately $900 million, including manufacturing investments and sustainability initiatives. - Expect quarter-to-quarter variability due to COVID-19 impacts and reimbursement dynamics. - Emphasis on growth from innovative products, biosimilars, and global expansion especially in China and Japan.

The transcript provided does not contain specific information regarding current or expected orderbook or pending orders for Amgen. The discussion primarily covers: - Recent product launches and sales performance (e.g., sotorasib, Tezepelumab, Otezla). - Clinical development progress and regulatory filings. - Commercial strategies and market expansion (e.g., growth in China and Japan). - Pipeline updates and research initiatives. - General comments on pricing pressures and competitive landscape. No explicit figures or commentary on orderbook size, backlog, or pending orders were disclosed in the provided transcript pages.